Dr. Luis Zapata leads the "Evolutionary Immunogenomics" team (Evilab.ai) at the Institute of Cancer Research in London. He earned his Bachelor's degree in Molecular Biotechnology Engineering from the University of Chile in Santiago. His passion for Computational Biology and Genomics was ignited during a short stay at UC Davis. He subsequently completed a PhD in Biomedicine at the Centre for Genomic Regulation in Barcelona, working under Dr. Stephan Ossowski as a “La Caixa” PhD fellow. During his PhD, he contributed to several studies leveraging genomic technologies to elucidate the role of genetic variation in disease and developed methods to detect drivers and essential genes through signals of selection. Dr. Zapata's research on negative selection led him to London, where he joined Professor Andrea Sottoriva's team at the Institute of Cancer Research as a Marie Curie Postdoctoral Fellow. His postdoctoral research focused on the co-evolutionary dynamics between the immune system and cancer cells, exploring how these interactions influence genomic variation. Notably, he demonstrated the use of evolutionary-based metrics to predict patient responses to immunotherapies. Currently, the EVIlab aims to understand the role of the immune system in both healthy tissues and cancers exposed to radiotherapy/chemotherapy. His team combines expertise in computational biology, evolutionary theory, immunology, and genetics, collaborating with clinical and experimental researchers to enhance cancer treatment. The lab's interdisciplinary approach seeks to improve therapeutic outcomes by elucidating the mechanisms of immune system involvement in cancer progression and treatment response.